Study on Emicizumab for Patients with Mild or Moderate Hemophilia A Without FVIII Inhibitors

3 1 1 1

What is this study about?

This clinical trial is focused on studying the effects of a medication called Hemlibra, which contains the active substance emicizumab. The study is specifically for patients with hemophilia A, a condition where the blood does not clot properly, leading to excessive bleeding. This trial is for those with mild or moderate forms of hemophilia A who do not have inhibitors against factor VIII, a protein that helps blood clot.

The purpose of the study is to evaluate the safety and effectiveness of emicizumab in preventing bleeding episodes in these patients. Participants will receive emicizumab as a solution for injection under the skin. The study will monitor the number of bleeding episodes over time and assess any side effects or reactions to the medication. The trial will also look at how the medication affects joint health, quality of life, and physical activity.

Throughout the study, participants will be regularly assessed to ensure their safety and to gather information on how emicizumab is working in their bodies. The trial will also explore the presence of any antibodies that might develop against the medication. This research aims to provide valuable insights into the management of hemophilia A and improve treatment options for those affected by this condition.

1 joining the study

Upon joining the study, the patient will be assessed to confirm eligibility based on specific criteria, such as having mild or moderate hemophilia A without FVIII inhibitors and a weight of at least 3 kg.

A negative test for inhibitors is required within 8 weeks prior to enrollment, and there should be no documented inhibitors or specific FVIII issues in the last 5 years.

2 initial assessment

The patient will undergo a comprehensive initial assessment, including documentation of previous treatments and bleeding episodes for at least the last 24 weeks.

Baseline measurements will be taken, including physical examination findings, vital signs, and ECG parameters.

3 medication administration

The patient will receive emicizumab, administered as a subcutaneous injection. The specific dosage and frequency will be determined by the study protocol.

The medication is available in two forms: Hemlibra 150 mg/mL and Hemlibra 30 mg/mL solutions for injection.

4 monitoring and follow-up

Regular monitoring will occur to evaluate the safety and efficacy of the treatment. This includes tracking the number of treated bleeds over time and assessing any adverse events.

The patient’s joint health and quality of life will be assessed at specified timepoints using standardized tools.

5 end of study

The study is estimated to conclude by December 31, 2025. At the end of the study, a final assessment will be conducted to evaluate the overall impact of the treatment.

The study aims to gather data on the incidence of adverse events, changes in physical health, and the patient’s preference for emicizumab compared to previous treatments.

Who Can Join the Study?

Have a diagnosis of mild or moderate hemophilia A. This means your FVIII level should be between more than 5% and less than 40% for mild, or between 1% and 5% for moderate. FVIII is a protein important for blood clotting.
Weigh at least 3 kg (about 6.6 pounds).
Need regular treatment to prevent bleeding, as decided by the doctor.
Have a negative test for inhibitors within 8 weeks before joining the study. An inhibitor is a substance that can stop the treatment from working.
No record of having inhibitors, a FVIII half-life of less than 6 hours, or FVIII recovery of less than 66% in the past 5 years. Half-life is the time it takes for the amount of FVIII to reduce by half in the body. Recovery is how well FVIII works after treatment.
Have records of your treatment details and the number of bleeding episodes for at least the last 24 weeks before joining the study.

Who Cannot Join the Study?

Patients with severe hemophilia A cannot participate. This means the study is only for those with mild or moderate forms of the condition.
Patients who have FVIII inhibitors are excluded. FVIII inhibitors are substances in the blood that can stop the treatment from working properly.
Patients who are not within the specified age range cannot participate. The study is for certain age groups only.
Patients who are not part of the specified clinical trial groups are excluded. This means only certain groups of patients are eligible.
Patients who are considered part of a vulnerable population may be excluded. Vulnerable populations include groups that might need special protection or care.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name	City	Country	Status
Katholieke Universiteit te Leuven	Leuven	Belgium

Other Sites

Site Name	City	Country
Rheinische Friedrich-Wilhelms-Universitaet Bonn	Bonn	Germany
Hopital Beaujon	Clichy	France
Coaypssaa Urhzocmukxgoao Sukgxiklt	Woluwe-Saint-Lambert	Belgium

Trial status

Country	Status	Recruitment Start
Belgium	Not recruiting	14.07.2020
France	Not recruiting	14.07.2020
Germany	Not recruiting	14.07.2020

Trial locations

Investigated drugs:

Emicizumab

Emicizumab is a medication used in this clinical trial to help manage hemophilia A, a bleeding disorder. It works by mimicking the activity of a protein called factor VIII, which is missing or not working properly in people with hemophilia A. This medication helps to prevent bleeding episodes by promoting blood clotting. The trial aims to assess how safe and effective emicizumab is for patients with mild or moderate hemophilia A who do not have inhibitors against factor VIII.

Hemophilia A – Hemophilia A is a genetic disorder where the blood does not clot properly due to a deficiency of clotting factor VIII. This condition leads to prolonged bleeding after injuries, surgeries, or even spontaneously without any apparent cause. In mild or moderate cases, bleeding episodes may occur less frequently and are often associated with trauma or surgery. Individuals with this condition may experience joint bleeds, which can lead to joint damage over time if not managed properly. The severity of the disease is determined by the level of factor VIII activity in the blood, with mild cases having higher levels than severe cases. Regular monitoring and management are essential to prevent complications associated with bleeding episodes.

Trial ID:

2023-506610-52-00

Protocol code:

BO41423

Trial Phase:

Therapeutic confirmatory (Phase III)

Other Trials to Consider

#1 Clinical Trials Search in Europe

Study on Emicizumab for Patients with Mild or Moderate Hemophilia A Without FVIII Inhibitors

What is this study about?

Who Can Join the Study?

Who Cannot Join the Study?